F10 and chronic kidney disease: A systematic review of direct oral anticoagulants (DOACs) in non-valvular AF patients with moderate chronic kidney disease revealed that dabigatran 150 mg twice daily and an inhibitor of factor Xa, apixaban were superior to warfarin for stroke and systemic embolic events prevention, while apixaban and edoxaban significantly reduced the risk of major hemorrhage more than warfarin [21,22].